Eventide Asset Management LLC Has $13.53 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Eventide Asset Management LLC lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 66.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,035 shares of the biopharmaceutical company’s stock after selling 67,704 shares during the quarter. Eventide Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $13,534,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in ALNY. HM Payson & Co. acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $27,000. Golden State Wealth Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 36 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. Ameriflex Group Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $32,000. Finally, Manchester Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 72 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Wells Fargo & Company upped their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a research note on Friday, May 1st. Royal Bank Of Canada lowered their price objective on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Citigroup began coverage on Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price objective for the company. Canaccord Genuity Group upped their target price on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Finally, Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $463.13.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the transaction, the insider directly owned 9,443 shares in the company, valued at approximately $3,120,156.06. This represents a 19.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 7,740 shares of company stock worth $2,420,214 over the last 90 days. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $282.85 on Monday. The business’s 50 day simple moving average is $304.31 and its 200 day simple moving average is $343.04. Alnylam Pharmaceuticals, Inc. has a one year low of $281.77 and a one year high of $495.55. The stock has a market capitalization of $37.76 billion, a PE ratio of 77.28 and a beta of 0.29. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the prior year, the business posted ($0.44) earnings per share. The firm’s revenue was up 96.4% on a year-over-year basis. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.